Photo from jnj.com
Jul 17, 2024, 21:50
Ivan R. Gonzalez: Lung cancer effectiveness of immunotherapy in early stage
Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:
”Advances in lung cancer effectiveness of immunotherapy in early stage!
- Inhibition of immune checkpoint is essential in the multimodal treatment of early-stage NSCLC.
- Combining neoadjuvant immunotherapy with platinum-based chemotherapy is recommended over chemotherapy alone.
- This combination reduces the risk of surgical omission and enhances surgical outcomes.
- The introduction of immunotherapy in early-stage NSCLC treatment has improved long-term survival, both event-free and disease-free.
- Many unanswered questions persist regarding the optimal strategy, underscoring the importance of case-by-case discussions in multidisciplinary tumor committees.
Immune checkpoint inhibition in early-stage non-small cell lung cancer.
Authors: Kristof Cuppens, Bert Du Pont, Joost Knegjens, Brigitte Maes, Paul Baas.”
Source: Ivan R. Gonzalez/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43
Dec 3, 2024, 09:35
Dec 3, 2024, 09:23
Dec 3, 2024, 09:20